BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 24899250)

  • 1. Emerging targeted therapies for melanoma treatment (review).
    Russo A; Ficili B; Candido S; Pezzino FM; Guarneri C; Biondi A; Travali S; McCubrey JA; Spandidos DA; Libra M
    Int J Oncol; 2014 Aug; 45(2):516-24. PubMed ID: 24899250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX; Qi XY
    IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma: molecular pathogenesis and emerging target therapies (Review).
    Russo AE; Torrisi E; Bevelacqua Y; Perrotta R; Libra M; McCubrey JA; Spandidos DA; Stivala F; Malaponte G
    Int J Oncol; 2009 Jun; 34(6):1481-9. PubMed ID: 19424565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
    Favre G
    Bull Acad Natl Med; 2014 Feb; 198(2):321-36; discussion 337-8. PubMed ID: 26263707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
    Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
    Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
    McKibbin T
    Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging targeted therapies for melanoma.
    Johnson DB; Pollack MH; Sosman JA
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies for cutaneous melanoma.
    Kee D; McArthur G
    Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Systemic Management of Advanced Melanoma in 2016.
    Heppt MV; Dietrich C; Graf SA; Ruzicka T; Tietze JK; Berking C
    Oncol Res Treat; 2016; 39(10):635-642. PubMed ID: 27710977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for melanoma: rational combinatorial approaches.
    Kwong LN; Davies MA
    Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Understanding current therapies in metastatic melanoma].
    Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
    Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment.
    Read J
    Australas J Dermatol; 2013 Aug; 54(3):163-72. PubMed ID: 23330781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
    Gutzmer R
    J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
    Goldman C; Tchack J; Robinson EM; Han SW; Moran U; Polsky D; Berman RS; Shapiro RL; Ott PA; Osman I; Zhong H; Pavlick AC; Wilson MA
    Oncology; 2017; 93(3):164-176. PubMed ID: 28601879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting drivers of melanoma with synthetic small molecules and phytochemicals.
    Strickland LR; Pal HC; Elmets CA; Afaq F
    Cancer Lett; 2015 Apr; 359(1):20-35. PubMed ID: 25597784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Targeted molecular therapies (except immunotherapy)].
    Roux J; Pages C; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
    Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
    Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the targeted therapy of melanoma.
    Johnson DB; Sosman JA
    Curr Treat Options Oncol; 2013 Jun; 14(2):280-92. PubMed ID: 23420410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.